Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, securing a portfolio of clinical-stage orexin receptor 2 agonists. This strategic move aims to accelerate the development of new treatments for narcolepsy and other sleep-wake disorders.
As mechanism-based orexin agonists get close to market, sleep physicians may feel compelled to reduce ambiguity between narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia diagnoses.
Samples from deceased brain donors reveal specific T-cells that can target orexin/hypocretin-expressing cells.
It will analyze once-daily and split-dose regimens of the oral orexin 2 receptor agonist in people with narcolepsy type 1 and type 2.
Read More
The dose escalation study will evaluate the efficacy, safety, and tolerability of a novel selective orexin-2 receptor agonist in adults with narcolepsy type 1 and type 2.
Read More
Low prescribing rates persist even as evidence supports benefit, pointing to missed conversations, unclear expectations, and fragile early treatment periods.
Read More
The low-sodium oxybate oral solution generated $1.7 billion in revenue, contributing to the company’s $3.1 billion neuroscience portfolio performance in 2025.
Read More
E2086, a selective orexin 2 receptor agonist, aims to address the pathophysiology of narcolepsy by activating orexinergic neurons.
Read More
The acquisition accelerates Alkermes’ entry into the sleep medicine market and incorporates the FDA-approved extended-release sodium oxybate treatment for narcolepsy.
Read More
The investigational oral OX2R-selective agonist is designed to restore orexin signaling; the FDA has set a target action date for the third quarter of 2026.
Read More
The approval allows Amneal to offer a generic alternative for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients, expanding access to this standard of care therapy.
Read More
The company’s narcolepsy treatment shows strong growth, while its late-stage pipeline advances with five phase 3 trials and a novel orexin agonist.
Read More
The deal will bring the narcolepsy treatment LUMRYZ under the Alkermes portfolio.
Read More
The upcoming submission for AXS-12 (reboxetine) for cataplexy in narcolepsy follows supportive feedback from the FDA.
Read More
The designation for the investigational oral orexin 2 receptor agonist aims to expedite development based on positive phase 2 clinical trial data.
Read More
The company also announced a CEO transition to sharpen its focus on its orexin pipeline as phase 2a data shows ORX750 improved key measures of wakefulness and cataplexy.
Read More
Positive trial results position the next-generation pitolisant formulation for a New Drug Application in early 2026.
Read More
The pharmaceutical giant deepens collaboration with Beacon Biosignals and partners with EnsoData to address challenges in narcolepsy type 1.
Read More